Table 1.
Code number | Commodity | Existing EU MRL (mg/kg) | Existing CXL (mg/kg) | Outcome of the review | |
---|---|---|---|---|---|
MRL (mg/kg) | Comment | ||||
Enforcement residue definition: thiophanate‐methyl | |||||
110010 | Grapefruits | 6 | – | – | Further consideration neededa Data gap #1 |
110020 | Oranges | 6 | 1 | – | Further consideration neededb Data gap #1 |
110030 | Lemons | 6 | – | Option 1c: – | Further consideration neededd Data gap #1 |
Option 2e: 7 | Further consideration neededf Data gap #1 | ||||
110040 | Limes | 6 | – | 7 | Further consideration neededf Data gap #1 |
110050 | Mandarins | 6 | – | – | Further consideration neededa Data gap #1 |
163030 | Mangoes | 1 | 5 | – | Further consideration neededb Data gap #1 |
163040 | Papayas | 1 | – | – | Further consideration neededa Data gap #1 |
231040 | Okra/lady's fingers | 1 | – | 0.9 | Further consideration neededd Data gap #1 |
Enforcement residue definition (existing): thiophanate‐methyl and carbendazim, expressed as carbendazim Enforcement residue definition (proposed): thiophanate‐methyl | |||||
1011010 | Swine muscle | 0.05* | – | 0.01* | Further consideration neededd Data gap #1 |
1011020 | Swine fat tissue | 0.05* | – | 0.01* | Further consideration neededd Data gap #1 |
1011030 | Swine liver | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1011040 | Swine kidney | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1012010 | Bovine muscle | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1012020 | Bovine fat tissue | 0.05* | – | 0.01* | Further consideration neededd Data gap #1 |
1012030 | Bovine liver | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1012040 | Bovine kidney | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1015010 | Equine muscle | 0.05* | – | 0.01* | Further consideration neededd Data gap #1 |
1015020 | Equine fat tissue | 0.05* | – | 0.01* | Further consideration neededd Data gap #1 |
1015030 | Equine liver | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1015040 | Equine kidney | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1020010 | Cattle milk | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
1020040 | Horse milk | 0.05* | 0.05* | 0.01* | Further consideration neededf Data gap #1 |
Enforcement residue definition (existing): sum of benomyl and carbendazim, expressed as carbendazim Enforcement residue definition (proposed): carbendazim | |||||
110010 | Grapefruits | 0.2 | – | – | Further consideration neededa Data gap #1 |
110020 | Oranges | 0.2 | 1 | – | Further consideration neededb Data gap #1 |
110030 | Lemons | 0.7 | – | Option 1c: 0.9 | Further consideration neededd Data gap #1 |
Option 2e: 0.2 | Further consideration neededd Data gap #1 | ||||
110040 | Limes | 0.7 | – | 0.9 | Further consideration neededd Data gap #1 |
110050 | Mandarins | 0.7 | – | 0.9 | Further consideration neededd Data gap #1 |
163030 | Mangoes | 0.5 | 5 | – | Further consideration neededb Data gap #1 |
163040 | Papayas | 0.2 | – | – | Further consideration neededa Data gap #1 |
231040 | Okra/lady's fingers | 2 | – | 1.5 | Further consideration neededd Data gap #1 |
Enforcement residue definition (existing): carbendazim and thiophanate‐methyl, expressed as carbendazim Enforcement residue definition (proposed): sum of carbendazim and 5‐hydroxy‐carbendazim, expressed as carbendazim | |||||
1011010 | Swine muscle | 0.05* | – | 0.02* | Further consideration neededd Data gaps #1,2 |
1011020 | Swine fat tissue | 0.05* | – | 0.02* | Further consideration neededd Data gaps #1,2 |
1011030 | Swine liver | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2 |
1011040 | Swine kidney | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2 |
1012010 | Bovine muscle | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2 |
1012020 | Bovine fat tissue | 0.05* | – | 0.02* | Further consideration neededd Data gaps #1,2 |
1012030 | Bovine liver | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2 |
1012040 | Bovine kidney | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2 |
1015010 | Equine muscle | 0.05* | – | 0.02* | Further consideration neededd Data gaps #1,2 |
1015020 | Equine fat tissue | 0.05* | – | 0.02* | Further consideration neededd Data gaps #1,2 |
1015030 | Equine liver | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2 |
1015040 | Equine kidney | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2 |
1020010 | Cattle milk | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2,3 |
1020040 | Horse milk | 0.05* | 0.05* | 0.02* | Further consideration neededf Data gaps #1,2,3 |
– | Other commodities of plant and/or animal origin | See Reg. 559/2011 | – | – | Further consideration neededg |
Enforcement residue definition (proposed): benomyl | |||||
– | Commodities of plant and/or animal origin | – | – | – | Further consideration neededg |
MRL: maximum residue level; CXL: codex maximum residue limit.
Indicates that the MRL is set at the limit of quantification.
The residue definition is fat soluble.
GAP evaluated at EU level is not fully supported by data and a risk to consumers cannot be excluded; no CXL is available. Either a specific LOQ or the default MRL of 0.01 mg/kg may be considered (combination E‐I in Appendix I).
GAP evaluated at EU level is not fully supported by data and a risk to consumers cannot be excluded; CXL is not compatible with EU residue definitions. Either a specific LOQ or the default MRL of 0.01 mg/kg may be considered (combination E‐II in Appendix I).
Option 1: MRL based on the authorised use for carbendazim, assuming that the authorised use of thiophanate‐methyl will be withdrawn.
Tentative MRL is derived from a GAP evaluated at EU level, which is not fully supported by data but for which no risk to consumers was identified; no CXL is available (combination F‐I in Appendix I). It is noted that carbendazim is classified as toxic for reproduction category 1B in accordance with Regulation (EC) No 1272/2008.
Option 2: MRL based on the authorised use for thiophanate‐methyl, assuming that the authorised use of carbendazim will be withdrawn.
Tentative MRL is derived from a GAP evaluated at EU level, which is not fully supported by data but for which no risk to consumers was identified; CXL is not compatible with EU residue definitions (combination F‐II in Appendix I). It is noted that carbendazim is classified as toxic for reproduction category 1B in accordance with Regulation (EC) No 1272/2008.
There are no import tolerances reported at EU level; no CXL is available or CXL is not compatible with EU residue definitions. Either a specific LOQ or the default MRL of 0.01 mg/kg may be considered (combination A‐I/II in Appendix I).